Objective: To observe the efficacy of insulin pump combined with dapagliflozin and insulin pump alone in the treatment of patients with type 2 diabetes. Methods 87 cases of type 2 diabetes were randomly divided into treatment group (55 cases) and observation group (32 cases). On the basis of strict control of diet and exercise, the treatment group was given dapagliflozin 10mg/d+ insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d and the observation group was treated with insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d. After 12 weeks of treatment, fasting blood glucose, postprandial 2h blood sugar and glycated hemoglobin were measured, the dosage of insulin was calculated, the weight and blood pressure were measured, and the incidence of hypoglycemia and urinary tract infection was observed. Results 1) After 12 weeks treatment, the fasting blood glucose, postprandial 2h blood sugar and glycated hemoglobin decreased significiantly in the treatment group and the observation group [(-4.51 ± 1.93) mmol/l, (-8.45 ± 3.17) mmol/l, (-2.42 ±1.07)% and (-4.29 ± 1.25) mmol/l, (-8.20 ± 3.65) mmol/l, (-2.41 ± 1.34)%]. 2) After 12 weeks treatment, the systolic pressure and diastolic pressure in the treatment group and the observation group decreased respectively [(-12.69 ± 16) mmHg, (-6.96 ± 9) mmHg and [(-2.34 ± 9.90) mmHg, (-2.06 ± 11.09) mmHg], the decrease degree between the two groups were significant difference (all P<0.05). 3) Weight loss after 12 weeks in the treatment group was (-4.00 ± 4.22) kg, while the weight in observation group slightly increased by (0.19 ± 1.61) kg (P<0.05). 4) The average daily insulin dosage in the treatment group and the observation group decreased after 12 weeks (-24.53 ± 12.48) IU and (-4.90 ± 10.87) IU respectively (P<0.05) and 18 cases of diabetes were discontinued insulin in the treatment group and 5 cases of diabetes were discontinued insulin in the observation group (P < 0.05). 5) There was 1 case hypoglycemia in the treatment group and 1 case hypoglycemia in the observation group. No urinary tract infection and ketosis were occurred in the two groups. Conclusion Combination insulin pump and dapagliflozin to treat type 2 diabetes can effectively reduce the blood sugar, weight, blood pressure, and insulin doses, and do not increase the risk of hypoglycemia.